Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program
Rafeek A. Yusuf(National Marrow Donor Program), Jeffery J. Auletta(Nationwide Children's Hospital), Jennifer A. Sees(National Marrow Donor Program), Christa L. Meyer(National Marrow Donor Program), Meggan McCann(National Marrow Donor Program), Jaime M. Preussler(National Marrow Donor Program), Katie Schoeppner(National Marrow Donor Program), Amber Ruffin(National Marrow Donor Program), Steven M. Devine(National Marrow Donor Program)
Cited by 12
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441